Case Report: Overt Acute Leukemia in Myelodysplastic Syndrome with t(8;21) After Low Dose G-CSF Therapy
Keywords:
Myelodysplastic syndrome, G-CSF, Acute leukemiaAbstract
Abstract : We reported a case of 54 year-old female who presented with fever, fatigue and anemia. She received a diagnosis of myelodysplastic syndrome (RAEB typeX with t(8:21) which this translocation is of ten found in ANLL but very rare in MDS. After blood transfusion and low dose G-CSF (1 ug/kg/d), the neutrool increased. Hower fifty days after treatment, she develovert acute
leukemia with spinal cord compression.
Downloads
References
Deiss A. Non-neoplastic diseases, chemical agents, and hematologic disorders that may precede hematologic neoplasms. In : Lee GR, Bithell TC, Foerster J, Atens JW, Lukens JN, eds. Wintrobe's Clinical Hematology. 9 ed. Philadelphia : Lea & Febiger. 1993:1946-68.
Greenberg PL. Treatment of myelodysplastic syndromes with hematopietic growth factors. Semin Oncol 1992;19:106-14
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haemstol 1982;51:189-99.
Mecucci C, Berghe HVD. Cytogenetics.Hematol/Oncol Clin North Am. 1992;6:523-41.
Gilchrist DM, Friedman JM, Rogers PCJ, Creighton SP. Myelodysplastic and leukemia syndrome with monosomy 7 : A genetic perspective. Am J Med Genet 1990;35:437-41.
Nucifora G, Rowley JD. AML 1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995;86:1-14.
Kwong YI, Ching LM, Liu HW,Lee CP, Pollock A, Chan LC, 8:21 translocation and multilineage involvent. Am J Hematol 1993;43:212-6.
Second MIC Cooperative Study Group: Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukemias Br J Haematol 1988;68:487-94.
Berger R, Flandrin G Bernheim A, et al. Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogenet 1987:29-21.
Kobayashi Y, Okabe T, Ozawa K, et al Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factors a preliminary report. Am J Med 1989;86:178-82.
Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor : A phase 1-ll trail. Ann Intern Med 1989;110:976.
Yuo A, Kittagawa S, Okabe T, et al Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous. Leukemia Blood 1987;70:404.
Yoshida Y, Hirashima K,Asano S, et al. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 1991;78:378.
Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patient with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990;76:36.
Vadhan-RAJ S, Keating M, La Maister A, et al. Effects of recombinant human granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987;317:1545
Schuster MW, Larson RA, Thrompson JA, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of a multicenter randomized controlled trial. Blood 1990;76:189.
Knapp RH, Dewald GW, Pierre RV, Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985,60:507-16.
Czepulkowski B, Gibbons B, Tucker J, Lister TA. Duplication of one of the productions of the t(821) translocation in a patient with refactory anemia with excess blassts in transformation. Cancer Genet Cytogenet 1987;25:175-7.
Maserati E, Casali M, Pasquali F, et al. Translocation (8,21) in two cases of reftactory anemia with excess of blasts of blasts in transformation Cancer Genet Cytogenet 1992;58:76-8.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
